logo
Share SHARE
FONT-SIZE Plus   Neg

Sanofi Reports Phase 3 Topline Trial Results Of Iniparib & Otamixaban

Sanofi (SNYNF,SNY: Quote) announced topline results of two Phase 3 studies of its investigational compounds iniparib and otamixaban respectively.

The randomized Phase 3 ECLIPSE trial of iniparib in squamous non-small cell lung cancer failed to meet its primary endpoint. During the study, newly diagnosed, metastatic Sq NSCLC patients treated with iniparib plus chemotherapy did not achieve improvement in overall survival compared to patients who received chemotherapy alone.

Topline results of the completed Phase 3 trial of the investigational anticoagulant otamixaban demonstrated that the study failed to meet its primary endpoint of superiority over current therapy. In the TAO study, due to efficacy lower than expected, otamixaban did not show superior benefit/risk to the combination of unfractionated heparin (UFH) +/- eptifibatide (a GP IIb/IIIa inhibitor) in non-ST elevation acute coronary syndrome patients planned for early invasive strategy. The primary endpoint of the Phase 3 TAO trial was the reduction of all-cause mortality or new heart attacks.

As a result, the company would terminate the investigational program with otamixaban, an injectable factor Xa inhibitor.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Social game developer Zynga Inc. said Wednesday after the markets closed that its first quarter loss narrowed from last year, as revenue increased and costs and expenses fell. The company's quarterly adjusted loss per share was also narrower than analysts estimated and its quarterly revenue beat analysts' forecast. Twenty-First Century Fox reported a better-than-expected third-quarter profit, on growth at its cable and film entertainment business, partly offset by the absence of Super Bowl as well as currency headwinds. Activision Blizzard Inc. (ATVI) on Wednesday reported a surge in profit for the first quarter, as revenues increased reflecting strong growth in digital business with the video game publisher's profit and revenues topping Wall Street estimates. Moving ahead, the company detailed a weak outlook for...
comments powered by Disqus
RELATED NEWS
Trade SNY now with 
Follow RTT